Here, we developed a novel MRI contrast agent composed of carbon-encapsulated iron nanoparticles functionalized with monoclonal antibodies against CD61 (Fe@C-(CH2)2-CONH-anti-CD61) to target the beta 3 subunit (CD61) of the integrin αvβ3 transmembrane receptor, which is highly overexpressed on glioma cells. This evidence concerns the gene ITGB3 and glioma.